Welcome to our dedicated page for Repligen SEC filings (Ticker: RGEN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission (SEC) filings for Repligen Corporation (NASDAQ: RGEN), a global life sciences company focused on bioprocessing technologies and systems for manufacturing biological drugs. As a Nasdaq-listed issuer, Repligen submits a range of regulatory documents that give detailed insight into its financial performance, governance and material events.
Among the key filings available are Form 10-K annual reports and Form 10-Q quarterly reports, which typically include audited or reviewed financial statements, management’s discussion and analysis, and information on Repligen’s bioprocessing focus areas: Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. These filings expand on the themes highlighted in the company’s earnings press releases and non-GAAP reconciliations.
Repligen also files Form 8-K current reports to disclose material events. Recent examples include 8-K filings referencing the release of second and third quarter 2025 financial results, as well as an 8-K describing the appointment of a Chief Accounting Officer to enhance the company’s financial reporting infrastructure and Sarbanes–Oxley oversight. Such filings can provide timely context on leadership changes, compensation decisions and other corporate developments.
Investors may also review proxy statements and, where applicable, Form 4 insider transaction reports to understand equity-based compensation and share activity by directors and officers. Together, these documents form the regulatory record of Repligen’s operations as a public company.
On Stock Titan, Repligen’s filings are updated as they are released on EDGAR, with AI-powered summaries that highlight key points from lengthy reports. This helps readers quickly identify major financial trends, governance changes and disclosures related to Repligen’s role as a life sciences and bioprocessing technology company.